Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Top Stages
1 past transactions
Keryx Biopharmaceuticals
Acquisition in 2018
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of treatments for kidney diseases. The company's primary product, Auryxia, is an orally administered, iron-based medication designed to manage serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis, as well as to treat iron deficiency anemia in adults with CKD who are not on dialysis. Keryx Biopharmaceuticals is committed to supporting independent research and provides resources such as co-pay assistance and patient support programs. The company was founded in 1997 and has established strategic partnerships for the development and commercialization of its products in various markets, including collaborations with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for Auryxia in Japan. As of December 2018, Keryx operates as a subsidiary of Akebia Therapeutics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.